Physician profile
Arnold D Craft
NPI 1104993203
$2,833.55
in general payments reported to CMS, 2019-2025
13 companies · $738 in 2025
The $738 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2021: $219 · 2022: $336 · 2023: $124 · 2024: $739 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,600.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $496.39 | 2024-2025 | |
| Allergan, INC. | $449.39 | 2019-2022 | |
| Alcon Vision LLC | $407.60 | 2019-2025 | Precision 1, Dailies Total1, Total30 |
| Bausch & Lomb Americas INC. | $337.95 | 2024-2025 | Miebo, Xiidra |
| Johnson & Johnson Vision Care, INC. | $262.65 | 2019-2025 | Acuvue |
| Oyster Point Pharma, INC. | $221.55 | 2022-2024 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $135.61 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $124.09 | 2019 | |
| Apellis Pharmaceuticals, INC. | $122.83 | 2024 | Syfovre |
| Eyevance Pharmaceuticals LLC | $122.00 | 2021 | |
| Sight Sciences, INC. | $120.28 | 2019 | |
| Shire North American Group INC | $18.21 | 2019 | |
| Alimera Sciences, INC. | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnold Craft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.